A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions

Duchenne Muscular Dystrophy (DMD)

Interventions

GENETIC

GEN6050X intravenous injection

GEN6050X is an intravenously administered human DMD exon 50 skipping base editing drug.

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER